Advertisement

Table of Contents

October 18, 2018; 132 (16)

BLOOD COMMENTARIES

SPECIAL REPORT

REVIEW ARTICLE

HOW I TREAT

CLINICAL TRIALS AND OBSERVATIONS

  • A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
    A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
    Lucia Masarova, Srdan Verstovsek, Juliana E. Hidalgo-Lopez, Naveen Pemmaraju, Prithviraj Bose, Zeev Estrov, Elias J. Jabbour, Farhad Ravandi-Kashani, Koichi Takahashi, Jorge E. Cortes, Jing Ning, Maro Ohanian, Yesid Alvarado, Lingsha Zhou, Sherry Pierce, Romany Gergis, Keyur P. Patel, Rajyalakshmi Luthra, Tapan M. Kadia, Courtney D. DiNardo, Gautam Borthakur, Kapil Bhalla, Guillermo Garcia-Manero, Carlos E. Bueso-Ramos, Hagop M. Kantarjian and Naval Daver

IMMUNOBIOLOGY AND IMMUNOTHERAPY

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

  • Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
    Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML
    Felicitas Thol, Razif Gabdoulline, Alessandro Liebich, Piroska Klement, Johannes Schiller, Christian Kandziora, Lothar Hambach, Michael Stadler, Christian Koenecke, Madita Flintrop, Mira Pankratz, Martin Wichmann, Blerina Neziri, Konstantin Büttner, Bennet Heida, Sabrina Klesse, Anuhar Chaturvedi, Arnold Kloos, Gudrun Göhring, Brigitte Schlegelberger, Verena I. Gaidzik, Lars Bullinger, Walter Fiedler, Albert Heim, Iyas Hamwi, Matthias Eder, Jürgen Krauter, Richard F. Schlenk, Peter Paschka, Konstanze Döhner, Hartmut Döhner, Arnold Ganser and Michael Heuser

RED CELLS, IRON, AND ERYTHROPOIESIS

BLOOD WORK

CONTINUING MEDICAL EDUCATION (CME) QUESTIONS